Ionis Pharmaceuticals (LTS:0JDI) Interest Expense : $-80.3 Mil (TTM As of Mar. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Ionis Pharmaceuticals's interest expense for the three months ended in Mar. 2024 was $ -20.6 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-80.3 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Ionis Pharmaceuticals's Operating Income for the three months ended in Mar. 2024 was $ -149.5 Mil. Ionis Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $ -20.6 Mil. Ionis Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ionis Pharmaceuticals Interest Expense Historical Data

The historical data trend for Ionis Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Interest Expense Chart

Ionis Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-12.44

-6.20

-4.40

-2.80

-75.60

Ionis Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-15.82	-18.56	-20.38	-20.85	-20.56

Ionis Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-80.3 Mil.

Ionis Pharmaceuticals (LTS:0JDI) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ionis Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $-20.6 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-149.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $1,399.6 Mil.

Ionis Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Ionis Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Ionis Pharmaceuticals (LTS:0JDI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (LTS:0JDI) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

IONS:USA IONS:Mexico ISI:Germany

Address

2855 Gazelle Court, Carlsbad, CA, USA, 92010

Website

https://www.ionispharma.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Ionis Pharmaceuticals (LTS:0JDI) Headlines

No Headlines